About Glycerol-3-phosphate acyltransferase 3
Glycerol-3-phosphate acyltransferase 3 (GPAT3) is a protein
from Homo sapiens identified by UniProt accession
Q53EU6, 434 residues long.
MolForge cross-references it against 0 known binders and
99 disease associations.
Target properties
| Protein name | Glycerol-3-phosphate acyltransferase 3 |
| UniProt accession | Q53EU6 |
| Gene | GPAT3 |
| Organism | Homo sapiens |
| Length | 434 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (99)
Diseases linked to this target (Open Targets).
- heel bone mineral density · score 0.45
- reticulocyte count · score 0.12
- neoplasm · score 0.10
- cyst · score 0.10
- upper aerodigestive tract neoplasm · score 0.06
- non-alcoholic fatty liver disease · score 0.06
- infect · score 0.04
- infection · score 0.04
- clear cell renal carcinoma · score 0.04
- Generalized congenital lipodystrophy with myopathy · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q53EU6-F1 | alphafold | PREDICTED | 85.31 | — |
Amino-acid sequence (434 residues)
MEGAELAGKI LSTWLTLVLG FILLPSVFGV SLGISEIYMK ILVKTLEWAT IRIEKGTPKE SILKNSASVG IIQRDESPME KGLSGLRGRD FELSDVFYFS KKGLEAIVED EVTQRFSSEE LVSWNLLTRT NVNFQYISLR LTMVWVLGVI VRYCVLLPLR VTLAFIGISL LVIGTTLVGQ LPDSSLKNWL SELVHLTCCR ICVRALSGTI HYHNKQYRPQ KGGICVANHT SPIDVLILTT DGCYAMVGQV HGGLMGIIQR AMVKACPHVW FERSEMKDRH LVTKRLKEHI ADKKKLPILI FPEGTCINNT SVMMFKKGSF EIGGTIHPVA IKYNPQFGDA FWNSSKYNMV SYLLRMMTSW AIVCDVWYMP PMTREEGEDA VQFANRVKSA IAIQGGLTEL PWDGGLKRAK VKDIFKEEQQ KNYSKMIVGN GSLS
Explore Glycerol-3-phosphate acyltransferase 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets